硫普罗宁联合甘利欣治疗肝癌肝动脉化疗栓塞后肝损害的临床研究

Clinical efficacy of Tiopionin combined with Diammonium Glycurrhizinate on liver injury caused by transcatheter arterial chemoembolization in liver carcinoma

目的探讨硫普罗宁联合甘利欣对肝癌肝动脉化疗栓塞后肝损害的治疗效果及安全性。方法 80例原发性肝癌接受经动脉栓塞化疗(TACE)后肝损害的患者随机分为两组,治疗组42例给予硫普罗宁0.2 g加入到5%葡萄糖250 mL静脉滴注,1次/d,甘利欣150 mg加入到5%葡萄糖250 mL静脉滴注,1次/d;对照组38例单用甘利欣150 mg加入到5%葡萄糖250 mL静脉滴注,1次/d,10 d后观察疗效。结果治疗组总有效率90.5%与对照组相比差异有显著性(P<0.05),治疗结束时治疗组TBIL、ALT、AST较对照组明显降低。结论硫普罗宁联合甘利欣对TACE后肝损害有较好的治疗效果及安全性。

【Objective】 To investigate the efficacy and safety of Tiopionin combined with Diammonium Glycurrhizinate on liver injury caused by transcatheter arterial chemoembolization（TACE） in liver carcinoma.【Methods】 80 patients with liver carcinoma,who suffered from liver injury after TACE operation were randomly divided into two groups.The treatment group was treated with 0.2 g Tiopionin and 150 mg Diammonium Glycurrhizinate daily by intravenous drip.The control group was given 150 mg Diammonium Glycurrhizinate daily by intravenous drip.The therapeutic efficacy was evaluated after 10 days.【Results】 The response rate of the treatment group was 90.5%,which was statistically significant（P 0.05） compared with control group.At the end of treatment,the levels of TBIL,ALT and AST were more declined in treatment group than control group.【Conclusions】 Combined therapy with Tiopionin and Diammonium Glycurrhizinate has good efficacy and safety on liver injury caused by TACE operation.